Following on from information provided to NICE by the company in May 2016, the appraisal of Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.